メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
鈴木 小夜
薬学科
ウェブサイト
https://k-ris.keio.ac.jp/html/100012960_ja.html
h-index
137
被引用数
8
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2011
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(26)
類似のプロファイル
(6)
フィンガープリント
Sayo Suzukiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Observational Study
83%
Azathioprine
66%
Rheumatoid Arthritis
66%
Non Small Cell Lung Cancer
66%
Pharmaceutics
66%
Cefmetazole
66%
Adverse Event
50%
Chronic Myeloid Leukemia
47%
Retrospective Study
37%
Dacomitinib
33%
Osimertinib
33%
Bosutinib
33%
Active Metabolite
33%
Pharmacokinetics
33%
Carbon
33%
Pembrolizumab
33%
Oxaliplatin
33%
Carbon 11
33%
Nilotinib
33%
Imatinib
33%
Amine Oxidase (Flavin Containing)
33%
Dysmenorrhea
33%
Dasatinib
33%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
33%
Kampo Medicine (Drug)
33%
Nivolumab
33%
Anemia
33%
Carbon 13
33%
Protein Tyrosine Kinase Inhibitor
33%
Carbon 14
33%
Ingenol Mebutate
33%
Ponatinib
33%
Pharmacogenomics
33%
Infliximab
33%
Cohort Study
33%
Dyslipidemia
33%
Penicillinase
33%
Urinary Tract Infection
33%
Escherichia coli
33%
Diabetes Mellitus
31%
Inosine
29%
Overall Survival
20%
High Performance Liquid Chromatography
19%
Symptom
16%
Malignant Neoplasm
13%
Progression Free Survival
13%
Clinical Pharmacology
11%
Pharmacotherapy
11%
Methotrexate
11%
Comorbidity
11%
Keyphrases
Colorectal Cancer Cells
66%
S100A10
66%
L-OHP
51%
Oxaliplatin
37%
Antibodies to Infliximab
33%
Hemoglobin Level
33%
Antibody Level
33%
Site Practice
33%
Medication Counseling
33%
Pembrolizumab
33%
Preclinical Training
33%
Oxaliplatin Resistance
33%
Counseling Practices
33%
Junior Students
33%
Prognostic Value
33%
Rheumatoid Arthritis
33%
Monoamine Oxidase Inhibitors
33%
Renal Anemia
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
33%
Nivolumab
33%
Prognosis Model
33%
ESBL-E
33%
Successful Experience
33%
Chronic Myeloid Leukemia
33%
Forced Expression
33%
Enactive
33%
Pharmacy Practice Experience
33%
Neutrophil-to-lymphocyte Ratio
33%
Anti-infliximab Antibodies
33%
Ingenol Mebutate
33%
Renal Disease
33%
Pica Behavior
33%
Imatinib Therapy
33%
Medical Professionalism
33%
Cross-training
33%
Boiogito
33%
Imatinib
26%
Prognostic Score
22%
Infliximab
20%
Small Group Discussion
20%
Methotrexate
20%
Estimated Glomerular Filtration Rate
20%
Overall Survival
16%
Professionalism Education
16%
Bofutsushosan
16%
Advanced Medication
13%
AZ5104
13%
Survival Outcomes
11%
Pharmaceutical Expertise
11%
Cox Proportional Hazards Model
11%
Medicine and Dentistry
Drug Therapy
100%
Self Concept
66%
Observational Study
38%
Likert Scale
38%
Lymphocyte
33%
Oxaliplatin
33%
Mental Capacity
33%
Pembrolizumab
33%
Public Health
33%
Non Small Cell Lung Cancer
33%
Kampo
33%
Nivolumab
33%
Counseling
33%
Dysmenorrhea
33%
Retrospective Study
33%
Neutrophil
33%
Daisaikoto
23%
Colorectal Cancer Cell Line
20%
Symptom
16%
Adverse Event
16%
Visual Analog Scale
16%
Overall Survival
14%
Ion Trap
13%
Liquid Chromatography-Mass Spectrometry
13%
Progression Free Survival
9%
Proportional Hazards Model
9%
Keishi Bukuryo Gan
8%
Medical Record
8%
Tokishakuyaku San
8%
Whole Cell
6%
IC50
6%
Surface Enhanced Laser Desorption Ionization Time of Flight Mass Spectrometry
6%
Tandem Mass Spectrometry
6%
